Menu
Search
|

Menu

Close
X

Corvus Pharmaceuticals Inc CRVS.OQ (NASDAQ Stock Exchange Global Market)

10.31 USD
+0.06 (+0.59%)
As of 3:30 PM EDT
chart
Previous Close 10.25
Open 10.24
Volume 11,802
3m Avg Volume 42,697
Today’s High 10.57
Today’s Low 10.24
52 Week High 17.54
52 Week Low 7.45
Shares Outstanding (mil) 29.19
Market Capitalization (mil) 322.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.633
FY17
-2.719
FY16
-6.884
FY15
-0.391
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
--
8.04
Price to Book (MRQ)
vs sector
2.18
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.25
Return on Investment (TTM)
vs sector
-41.87
13.23
Return on Equity (TTM)
vs sector
-42.22
15.27

EXECUTIVE LEADERSHIP

Richard Miller
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $291,770.00
Bonus: --
Leiv Lea
Chief Financial Officer, Since 2015
Salary: $264,904.00
Bonus: --
Jason Coloma
Senior Vice President and Chief Business Officer, Since 2016
Salary: $214,031.00
Bonus: --
William Jones
Vice President of Pharmaceutical Development, Since 2015
Salary: --
Bonus: --
Erik Verner
Vice President of Chemistry Research, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

863 Mitten Rd Ste 102
BURLINGAME   CA   94010-1311

Phone: +1650.9004520

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

SPONSORED STORIES